JNJ ▲ +0.9% - Johnson & Johnson
$JNJ - TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
12-OCT-2026 04:05 PM ET
Share this post
More filings for $JNJ
JNJ ▲ +0.9% - Johnson & JohnsonOct 12, 2026JNJ ▼ -0.1% - Johnson & JohnsonOct 9, 2026JNJ ▲ +0.5% - Johnson & JohnsonOct 2, 2026JNJ ▲ +0.5% - Johnson & JohnsonOct 2, 2026JNJ ▼ -0.0% - Johnson & JohnsonSep 29, 2026JNJ ▲ +0.1% - Johnson & JohnsonSep 25, 2026
View full $JNJ filing history →💬 Comments
Loading comments…
Leave a comment